Jiangsu Bioperfectus Technologies Co Ltd
688399
Company Profile
Business description
Jiangsu Bioperfectus Technologies Co Ltd is engaged in product development, production and sales of disease prevention and control, female genital micro-ecological testing and tumor screening. Its products and solutions involve: HPV & cervical cancer screening, Respiratory infection detection solution, Solutions for infectious diarrhea, STI detection solution for reproductive tract infections, Infectious disease testing, Maternal and child health, Disease prevention and control, Instrument, Scientific research services, and Other.
Contact
No.1 Yaocheng Avenue
3rd floor, Block G19, Jiangsu
Taizhou
CHNT: +86 52386201616
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
581
Stocks News & Analysis
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,178.40 | 69.70 | 0.77% |
| CAC 40 | 8,625.06 | 115.42 | 1.36% |
| DAX 40 | 26,024.28 | 395.04 | 1.54% |
| Dow JONES (US) | 52,485.03 | 276.97 | 0.53% |
| FTSE 100 | 10,897.78 | 29.73 | 0.27% |
| HKSE | 26,009.40 | 124.97 | 0.48% |
| NASDAQ | 25,373.85 | 251.68 | 1.00% |
| Nikkei 225 | 63,754.90 | 607.12 | -0.94% |
| NZX 50 Index | 13,774.93 | 75.65 | 0.55% |
| S&P 500 | 7,489.72 | 52.09 | 0.70% |
| S&P/ASX 200 | 9,019.30 | 70.30 | 0.79% |
| SSE Composite Index | 3,809.66 | 22.60 | -0.59% |